A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of Iluvien in chronic diabetic macular edema patients considered insufficiently responsive to available therapies with or without intravitreal corticosteroid therapy. (RESPOND)

Trial Profile

A non-randomised, open-label, multicenter phase 4 pilot study on the effect and safety of Iluvien in chronic diabetic macular edema patients considered insufficiently responsive to available therapies with or without intravitreal corticosteroid therapy. (RESPOND)

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Fluocinolone acetonide (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RESPOND
  • Most Recent Events

    • 11 Dec 2016 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.
    • 06 May 2016 Preliminary results from this trial were presented at the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), according to an Alimera Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top